1. Home
  2. ADXN vs NVNO Comparison

ADXN vs NVNO Comparison

Compare ADXN & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addex Therapeutics Ltd

ADXN

Addex Therapeutics Ltd

HOLD

Current Price

$6.21

Market Cap

8.6M

Sector

Health Care

ML Signal

HOLD

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

HOLD

Current Price

$10.54

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADXN
NVNO
Founded
2002
1987
Country
Switzerland
United States
Employees
N/A
33
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6M
7.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ADXN
NVNO
Price
$6.21
$10.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.7K
7.0K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$86.57
N/A
Revenue Next Year
N/A
$140.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.41
$0.30
52 Week High
$12.05
$13.44

Technical Indicators

Market Signals
Indicator
ADXN
NVNO
Relative Strength Index (RSI) 44.96 50.94
Support Level $5.78 $9.81
Resistance Level $7.40 $12.69
Average True Range (ATR) 0.25 0.51
MACD -0.05 -0.03
Stochastic Oscillator 24.82 55.86

Price Performance

Historical Comparison
ADXN
NVNO

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: